Plasma cytokine and angiogenic factor profiling identifies markers associated with tumor shrinkage in early-stage non-small cell lung cancer patients treated with pazopanib
about
Pazopanib in sarcomas: expanding the PALETTECirculating biomarkers in advanced renal cell carcinoma: clinical applicationsBiomarkers of evasive resistance predict disease progression in cancer patients treated with antiangiogenic therapies.Opportunities and challenges for successful use of bevacizumab in pediatrics.Efficacy and safety of angiogenesis inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis.Phase I study of pazopanib plus TH-302 in advanced solid tumors.Rationale and design of the Exercise Intensity Trial (EXCITE): A randomized trial comparing the effects of moderate versus moderate to high-intensity aerobic training in women with operable breast cancerAlveolar hypoxia promotes murine lung tumor growth through a VEGFR-2/EGFR-dependent mechanismChallenges in developing a validated biomarker for angiogenesis inhibitors: the motesanib experienceCytokine and angiogenic factors associated with efficacy and toxicity of pazopanib in advanced soft-tissue sarcoma: an EORTC-STBSG study.Serum protein profiling reveals baseline and pharmacodynamic biomarker signatures associated with clinical outcome in mCRC patients treated with chemotherapy ± cediranibEvaluation of KRAS mutations, angiogenic biomarkers, and DCE-MRI in patients with advanced non-small-cell lung cancer receiving sorafenibAnti-angiogenic agents in the treatment of non-small cell lung cancer.Antiangiogenic agents in combination with chemotherapy in patients with advanced non-small cell lung cancer.Identification of a variant in KDR associated with serum VEGFR2 and pharmacodynamics of PazopanibPrognostic significance of angiogenesis and angiogenic growth factors in nonsmall cell lung cancerThe BATTLE to personalize lung cancer prevention through reverse migration.Anti-VEGF treatment-resistant pancreatic cancers secrete proinflammatory factors that contribute to malignant progression by inducing an EMT cell phenotype.Biomarkers in tumor angiogenesis and anti-angiogenic therapy.Epidermal growth factor receptor and K-Ras in non-small cell lung cancer-molecular pathways involved and targeted therapiesClinical development of VEGF signaling pathway inhibitors in childhood solid tumors.Pazopanib diminishes non-small cell lung cancer (NSCLC) growth and metastases in vivoThe role of gene expression profiling in early-stage non-small cell lung cancer.CECs and IL-8 Have Prognostic and Predictive Utility in Patients with Recurrent Platinum-Sensitive Ovarian Cancer: Biomarker Correlates from the Randomized Phase-2 Trial of Olaparib and Cediranib Compared with Olaparib in Recurrent Platinum-SensitivAnalysis of circulating angiogenic biomarkers from patients in two phase III trials in lung cancer of chemotherapy alone or chemotherapy and thalidomide.Adding to the mix: fibroblast growth factor and platelet-derived growth factor receptor pathways as targets in non-small cell lung cancerA phase I study of BMS-690514 in Japanese patients with advanced or metastatic solid tumors.Anti-VEGF therapies in the clinicSerum C-Telopeptide Collagen Crosslinks and Plasma Soluble VEGFR2 as Pharmacodynamic Biomarkers in a Trial of Sequentially Administered Sunitinib and CilengitideSignatures of tumour immunity distinguish Asian and non-Asian gastric adenocarcinomas.KDR Amplification Is Associated with VEGF-Induced Activation of the mTOR and Invasion Pathways but does not Predict Clinical Benefit to the VEGFR TKI Vandetanib.A phase II trial comparing pazopanib with doxorubicin as first-line treatment in elderly patients with metastatic or advanced soft tissue sarcoma (EPAZ): study protocol for a randomized controlled trialPhase I pharmacokinetic and pharmacodynamic study of pazopanib in children with soft tissue sarcoma and other refractory solid tumors: a children's oncology group phase I consortium report.Clinical and biomarker outcomes of the phase II vandetanib study from the BATTLE trial.Controlling escape from angiogenesis inhibitors.Angiogenesis and immunity: a bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy.Developmental antiangiogenic agents for the treatment of non-small cell lung cancer (NSCLC).Pazopanib for the treatment of breast cancer.Antiangiogenic agents in the management of non-small cell lung cancer: where do we stand now and where are we headed?Aflibercept in lung cancer.
P2860
Q26825050-C5D43C43-F625-456B-9C6E-CD93BBB898D4Q27023770-3ED82F89-01DF-4F0A-BC89-6908157D7FEEQ27853358-FCF6E7A2-4B08-4AD1-8269-F2DB06372248Q30454883-16FBD231-0781-41DB-B062-CDC59660DDE2Q33418555-57D74210-8A3A-4AF5-9AD9-B4BD9304F3EAQ33439635-475CD3BC-558E-4958-AEAE-B82A74CBD167Q33711531-AD4E7F5B-BEC0-4C05-8C73-2E3FB3B84A4CQ34213977-1C31B158-3DDC-4A71-B95D-FAE7D95466D4Q34337865-5CBEE411-619A-491C-AFB1-B0B7E8228DF1Q34340390-A722199C-9671-487F-B8D7-C0F814D39253Q34354522-FD553DD4-E82F-45ED-861E-F3DDE482CCF0Q34625305-2510FF8A-6CE3-44FF-9D46-B9741ADE679FQ34821321-73B1B87A-7804-47B3-BB4F-1E3C8049A349Q34854658-7FF311FD-A297-4827-9BDE-4D803538A573Q35068932-7D206DC1-3877-40C9-A4D2-797DC2605B0FQ35177011-0DB27E0A-DE60-4D66-B274-8CA1F9061B5FQ35208501-95E3AB6B-D553-4335-A968-40F7EE0C09B4Q35227104-C644BC31-812C-47E5-96D0-2BBD43CF7236Q35536088-9EDCB932-5254-4AE2-8541-4755C9A52E4AQ35549063-9400B55C-E1A2-4BDE-BD26-4F9B26BD47D4Q35599819-2268133F-AB5F-4AE8-96D8-7DF8E77824FEQ35663577-5E1878B4-09DD-4893-99B7-F9E482DAA9D1Q35667675-4002D50D-A051-4D9E-87D7-D25294BAFC65Q35669792-D1DA824A-A3CA-4C2C-B72B-785976E8D793Q35832330-FD80A88B-66E0-4726-BF1B-FA7011BC5DB0Q36161541-B810BB36-F15B-485A-AB42-7CA6BD9870C2Q36275492-CCE37360-FEE4-49A8-A18C-7822B331263DQ36330281-792C8795-5AB4-4525-B9CA-4D29B385B9F4Q36368035-2A6A34D4-10A0-4351-9BCB-431971B2BDA2Q36374816-D186DEE9-D597-48D7-8776-3C9D545D2B29Q36805595-7D672E99-ADE6-4979-9A17-2921D06B5151Q37073827-7946ACC7-C801-4A96-AEDB-C69E0B23DA86Q37085863-3AB8EBFB-15D2-4FAC-AC2F-07169C1BF954Q37428434-966B1012-CFFB-45A0-BD26-94CF04F255A6Q37672654-9BED42BB-232E-43D8-8467-74C360BA3942Q37830361-9FCD0C90-9C64-4D75-90FB-E68A1029BE6DQ37944183-698366E1-8EAC-4E00-BADA-837DB34E18B8Q37974693-69C6E6AF-6C92-46D2-9319-591AF7D6C238Q38000486-A150630E-71D9-4D31-95B1-CBAB570C4636Q38063939-1A73CDDE-3107-4E36-A02F-CFB171EF3B45
P2860
Plasma cytokine and angiogenic factor profiling identifies markers associated with tumor shrinkage in early-stage non-small cell lung cancer patients treated with pazopanib
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Plasma cytokine and angiogenic ...... atients treated with pazopanib
@ast
Plasma cytokine and angiogenic ...... atients treated with pazopanib
@en
type
label
Plasma cytokine and angiogenic ...... atients treated with pazopanib
@ast
Plasma cytokine and angiogenic ...... atients treated with pazopanib
@en
prefLabel
Plasma cytokine and angiogenic ...... atients treated with pazopanib
@ast
Plasma cytokine and angiogenic ...... atients treated with pazopanib
@en
P2093
P2860
P1433
P1476
Plasma cytokine and angiogenic ...... atients treated with pazopanib
@en
P2093
David Yankelevitz
Dilip Rajagopalan
Hai T Tran
Lone H Ottesen
Nasser Altorki
Petros G Nikolinakos
Shaoyu Yan
Walter Bordogna
P2860
P304
P356
10.1158/0008-5472.CAN-09-2533
P407
P577
2010-03-09T00:00:00Z